Skip to main content
Erschienen in: Tumor Biology 2/2014

01.02.2014 | Research Article

Association of XRCC5 VNTR polymorphism with the development of chronic myeloid leukemia

verfasst von: Manjula Gorre, Prajitha Edathara Mohandas, Sailaja Kagita, Sandhya Annamaneni, Raghunadharao Digumarti, Vishnupriya Satti

Erschienen in: Tumor Biology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Double-strand breaks (DSBs) inducing agents influence the fidelity of DNA repair in both normal cells and leukemic cells, causing major genomic instability. In eukaryotic cells, non-homologous end joining pathway (NHEJ) is the major mechanism for DSB repair. Human X-ray repair cross-complementing 5 (XRCC5) gene encodes for the protein KU86, an important component of NHEJ pathway. Variable number of tandem repeats (VNTR) polymorphism (rs 6147172) in the promoter region of XRCC5 gene was shown to have effect on gene expression and was found to be associated with the development of several cancers. We analyzed VNTR polymorphism of XRCC5 gene in 461 chronic myeloid leukemia (CML) cases and 408 controls by polymerase chain reaction. Our results showed that frequency of 0R/0R genotype was significantly elevated in CML cases compared to that of controls (p = 0.05). Significant difference in the genotype distribution was observed between cases and controls (p = 0.02). The risk of CML development was found to be elevated for individuals carrying lower repeats (1R p = 0.03; 0R p = 0.007). Elevated 0R/0R genotype frequency was found to be significantly associated with early age at onset (≤30 years) and slightly elevated in chronic phase and poor hematologic response to imatinib mesylate. The influence of zero repeat on enhanced expression of XRCC5 might confer risk to error-prone repair leading to genomic instability and CML. Hence, the VNTR polymorphism in the promoter region of XRCC5 gene could serve as an important prognostic marker in CML development.
Literatur
1.
Zurück zum Zitat Faderl S, Talpaz M, Estrov Z, OBrien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164–72.PubMedCrossRef Faderl S, Talpaz M, Estrov Z, OBrien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164–72.PubMedCrossRef
2.
Zurück zum Zitat Khanna KK, Jackson SP. DNA double strand breaks: signaling, repair, and the cancer connection. Nat Genet. 2001;27:247–54.PubMedCrossRef Khanna KK, Jackson SP. DNA double strand breaks: signaling, repair, and the cancer connection. Nat Genet. 2001;27:247–54.PubMedCrossRef
3.
Zurück zum Zitat Nicola B, Terry JG, Manyee C, Ghulam JM, Feyruz VR. Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key non homologous end-joining proteins. Cancer Res. 2003;63:1798–805. Nicola B, Terry JG, Manyee C, Ghulam JM, Feyruz VR. Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key non homologous end-joining proteins. Cancer Res. 2003;63:1798–805.
4.
Zurück zum Zitat Cai QQ, Plet A, Imbert J, Lafage-Pochitaloff M, Cerdan C, Blanchard JM. Chromosomal location and expression of the genes coding for Ku p70 and p80 in human cell lines and normal tissues. Cytogenet Cell Genet. 1994;65:221–7.PubMedCrossRef Cai QQ, Plet A, Imbert J, Lafage-Pochitaloff M, Cerdan C, Blanchard JM. Chromosomal location and expression of the genes coding for Ku p70 and p80 in human cell lines and normal tissues. Cytogenet Cell Genet. 1994;65:221–7.PubMedCrossRef
5.
Zurück zum Zitat Stronati L, Gensabella G, Lamberti C, Barattini P, Frasca D, Tanzarella C, et al. Expression and DNA binding activity of the Ku heterodimer in bladder carcinoma. Cancer. 2001;92:2484–92.PubMedCrossRef Stronati L, Gensabella G, Lamberti C, Barattini P, Frasca D, Tanzarella C, et al. Expression and DNA binding activity of the Ku heterodimer in bladder carcinoma. Cancer. 2001;92:2484–92.PubMedCrossRef
6.
Zurück zum Zitat Pucci S, Mazzarelli P, Rabitti C, Giai M, Gallucci M, Flammia G, et al. Tumor specific modulation of KU70/80 DNA binding activity in breast and bladder human tumor biopsies. Oncogene. 2001;20:739–47.PubMedCrossRef Pucci S, Mazzarelli P, Rabitti C, Giai M, Gallucci M, Flammia G, et al. Tumor specific modulation of KU70/80 DNA binding activity in breast and bladder human tumor biopsies. Oncogene. 2001;20:739–47.PubMedCrossRef
7.
Zurück zum Zitat Yang MD, Tsai CW, Chang WS, Tsou YA, Wu CN, Bau DT. Predictive role of XRCC5/XRCC6 genotypes in digestive system cancers. World J Gastrointest Oncol. 2011;3(12):175–81.PubMedCentralPubMedCrossRef Yang MD, Tsai CW, Chang WS, Tsou YA, Wu CN, Bau DT. Predictive role of XRCC5/XRCC6 genotypes in digestive system cancers. World J Gastrointest Oncol. 2011;3(12):175–81.PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Ludwig DL, Chen F, Peterson SR, Nussenzweig A, Li GC, Chen DJ. Ku80 gene expression is Sp1-dependent and sensitive to CpG methylation within a novel cis element. Gene. 1997;199:181–94.PubMedCrossRef Ludwig DL, Chen F, Peterson SR, Nussenzweig A, Li GC, Chen DJ. Ku80 gene expression is Sp1-dependent and sensitive to CpG methylation within a novel cis element. Gene. 1997;199:181–94.PubMedCrossRef
9.
Zurück zum Zitat Wang S, Wang M, Yin S, Fu G, Li C, Chen R, et al. A novel variable number of tandem repeats (VNTR) polymorphism containing Sp1 binding elements in the promoter of XRCC5 is a risk factor for human bladder cancer. Mutat Res. 2008;638:26–36.PubMedCrossRef Wang S, Wang M, Yin S, Fu G, Li C, Chen R, et al. A novel variable number of tandem repeats (VNTR) polymorphism containing Sp1 binding elements in the promoter of XRCC5 is a risk factor for human bladder cancer. Mutat Res. 2008;638:26–36.PubMedCrossRef
10.
Zurück zum Zitat Rajaei M, Saadat I, Saadat M. High-resolution melting analysis for detection of variable number of tandem repeats polymorphism of XRCC5. Biochem Biophys Res Commun. 2012;425:398–400.PubMedCrossRef Rajaei M, Saadat I, Saadat M. High-resolution melting analysis for detection of variable number of tandem repeats polymorphism of XRCC5. Biochem Biophys Res Commun. 2012;425:398–400.PubMedCrossRef
11.
Zurück zum Zitat Rajaei M, Saadat I, Saadat I. The novel allele (3R) of the VNTR polymorphism in the XRCC5promoter region dramatically decreases the gene expression. Biochem Biophys Res Commun. 2013;430:640–1.PubMedCrossRef Rajaei M, Saadat I, Saadat I. The novel allele (3R) of the VNTR polymorphism in the XRCC5promoter region dramatically decreases the gene expression. Biochem Biophys Res Commun. 2013;430:640–1.PubMedCrossRef
12.
Zurück zum Zitat Rajaei M, Saadat I, Saadat M. Introducing a novel allele for the polymorphism of variable number of tandem repeats in the promoter region of XRCC5. Biochem Biophys Res Commun. 2012;427:503–5.PubMedCrossRef Rajaei M, Saadat I, Saadat M. Introducing a novel allele for the polymorphism of variable number of tandem repeats in the promoter region of XRCC5. Biochem Biophys Res Commun. 2012;427:503–5.PubMedCrossRef
13.
Zurück zum Zitat Lahiri DK, Nurnberger Jr JI. A rapid nonenzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 1991;19(19):5444.PubMedCentralPubMedCrossRef Lahiri DK, Nurnberger Jr JI. A rapid nonenzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 1991;19(19):5444.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Wang G, Wang S, Shen Q, Yin S, Li C, Li A, et al. Polymorphisms inXRCC5, XRCC6, XRCC7 genes are involved in DNA double-strand breaks (DSBs) repair associated with the risk of acute myeloid leukemia (AML) in Chinese population. J Nanjing Med Univ. 2009;23(2):93–9.CrossRef Wang G, Wang S, Shen Q, Yin S, Li C, Li A, et al. Polymorphisms inXRCC5, XRCC6, XRCC7 genes are involved in DNA double-strand breaks (DSBs) repair associated with the risk of acute myeloid leukemia (AML) in Chinese population. J Nanjing Med Univ. 2009;23(2):93–9.CrossRef
Metadaten
Titel
Association of XRCC5 VNTR polymorphism with the development of chronic myeloid leukemia
verfasst von
Manjula Gorre
Prajitha Edathara Mohandas
Sailaja Kagita
Sandhya Annamaneni
Raghunadharao Digumarti
Vishnupriya Satti
Publikationsdatum
01.02.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 2/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1120-5

Weitere Artikel der Ausgabe 2/2014

Tumor Biology 2/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.